Revenue
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bio-Rad Laboratories, Inc. (BIO)
Price$379.82Cached quote
Net income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B | $2.55B | $2.31B | $2.29B | $2.16B | $2.07B | $2.02B | $2.18B | $2.13B | $2.07B | $2.07B | $1.93B | $1.78B | $1.76B |
| Gross profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B | $1.44B | $1.26B | $1.22B | $1.19B | $1.14B | $1.12B | $1.18B | $1.18B | $1.16B | $1.18B | $1.09B | $999.8M | $962.5M |
| Gross margin | 51.87% | 53.73% | 53.42% | 55.93% | 56.05% | 56.49% | 54.38% | 53.43% | 54.98% | 55.04% | 55.54% | 54.18% | 55.26% | 55.83% | 56.85% | 56.64% | 56.04% | 54.55% |
| Research & development | $275.6M | $295.9M | $247.4M | $256.9M | $260.6M | $217.8M | $202.7M | $199.2M | $250.2M | $205.7M | $193.0M | $220.3M | $211.0M | $209.2M | $177.6M | $172.3M | $163.6M | $159.5M |
| Operating expenses | $1.29B | $1.11B | $1.09B | $1.08B | $1.14B | $1.02B | $1.03B | $1.33B | $1.07B | $1.08B | $955.0M | $1.03B | $1.01B | $891.0M | $873.6M | $807.5M | $768.9M | $779.6M |
| Operating income | $47.2M | $269.0M | $337.8M | $482.6M | $500.3M | $421.3M | $229.7M | −$103.3M | $119.3M | $55.7M | $166.7M | $150.0M | $169.5M | $264.2M | $305.2M | $284.0M | $231.0M | $182.9M |
| Operating margin | 1.83% | 10.48% | 12.65% | 17.22% | 17.12% | 16.55% | 9.93% | −4.51% | 5.52% | 2.69% | 8.26% | 6.90% | 7.95% | 12.77% | 14.72% | 14.74% | 12.95% | 10.37% |
| EBITDA | $212.6M | $420.6M | $483.7M | $619.9M | $637.9M | $559.9M | $363.9M | $34.8M | $267.9M | $198.6M | $298.5M | $299.9M | $316.7M | $394.6M | $426.2M | $392.9M | $332.7M | — |
| EBITDA margin | 8.23% | 16.39% | 18.11% | 22.12% | 21.83% | 22.00% | 15.74% | 1.52% | 12.40% | 9.60% | 14.78% | 13.79% | 14.85% | 19.07% | 20.56% | 20.39% | 18.65% | — |
| Net income | $759.9M | −$1.84B | −$637.3M | −$3.63B | $4.25B | $3.81B | $1.76B | $365.6M | $122.2M | $26.0M | $109.2M | $88.8M | $77.8M | $165.5M | $179.0M | $185.5M | $144.6M | $89.5M |
| Net profit margin | 29.42% | −71.86% | −23.86% | −129.45% | 145.57% | 149.84% | 76.08% | 15.97% | 5.66% | 1.26% | 5.41% | 4.08% | 3.65% | 8.00% | 8.63% | 9.63% | 8.11% | 5.07% |
| Basic EPSper basic share | $27.87 | -$65.36 | -$21.82 | -$121.79 | $142.61 | $128.13 | $58.93 | $12.25 | $4.12 | $0.88 | $3.74 | $3.08 | $2.72 | $5.85 | $6.39 | $6.70 | $5.28 | $3.30 |
| Diluted EPSper diluted share | $27.85 | -$65.36 | -$21.82 | -$121.79 | $140.83 | $126.47 | $58.27 | $12.10 | $4.07 | $0.88 | $3.71 | $3.05 | $2.69 | $5.78 | $6.29 | $6.59 | $5.20 | $3.24 |
Owners
Reported shareholders
24.05%of listed shares
First Eagle Investment Management, LLC5.21M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
First Eagle Investment Management, LLC | 24.05%5.21M shares |
BlackRock, Inc. | 7.84%1.7M shares |
DIMENSIONAL FUND ADVISORS LP | 4.36%944.55K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.81%826.97K shares |
ARIEL INVESTMENTS, LLC | 3.77%816.75K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.77%816.2K shares |
EARNEST PARTNERS LLC | 2.68%580.75K shares |
STATE STREET CORP | 2.64%571.76K shares |
BANK OF AMERICA CORP /DE/ | 2.26%490.41K shares |
Assenagon Asset Management S.A. | 2.15%466.45K shares |
Capital World Investors | 2.13%462.46K shares |
Capital Research Global Investors | 2.05%443.48K shares |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.93%418.88K shares |
First Pacific Advisors, LP | 1.85%401.86K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.60%347.58K shares |
NOMURA HOLDINGS INC | 1.52%328.9K shares |
UBS Group AG | 1.42%308.33K shares |
SEI INVESTMENTS CO | 1.26%273.38K shares |
BARCLAYS PLC | 1.23%267.63K shares |
DEERFIELD MANAGEMENT COMPANY, L.P. | 1.04%226.07K shares |
Percentages use 21.68M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 11, 2026Form 4 | ENGELHARDT EVA ANETTEEVP, President, CDG | SellBio-Rad A Common Stock | 550 | $246.54 | $135.6K | 346 |
| Nov 6, 2025Form 4 | BARRY JAMESEVP, President, LSG | SellBio-Rad A Common Stock | 699.87 | $306.18 | $214.3K | 509.68 |
| Mar 14, 2025Form 4 | Crowley MichaelEVP, GBL Commercial Operations | SellBio-Rad A Common Stock | 3.0K | $247.06 | $741.2K | 8.2K |
| Sep 6, 2024Form 4 | Last Andrew J.EVP, Chief Operating Officer | SellBio-Rad A Common Stock | 3.0K | $329.94 | $989.8K | 7.6K |
| Sep 4, 2024Form 4 | BARRY JAMESEVP, President, LSG | SellBio-Rad A Common Stock | 623 | $330.49 | $205.9K | 146.56 |